Fucoidan for active rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a seaweed extract called fucoidan to see if it can help people with active rheumatoid arthritis that is not well controlled by their current treatments. If you have moderate-to-high disease activity despite therapy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and weigh at least 35 kg.
- You have been diagnosed with rheumatoid arthritis and have moderate-to-high disease activity (DAS28 score > 3.2).
- You are not currently on biologic treatments for RA.
- If you take pain relievers or steroids, your dose must have been stable for at least 2–4 weeks before starting the study.
- If you take methotrexate or leflunomide, you must have been on a stable dose for at least 4 weeks prior to the study.
- You cannot be pregnant, breastfeeding, or have other serious health conditions like uncontrolled diabetes, heart disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how the drug R-2487 behaves in the body and looks at early safety in adults with active rheumatoid arthritis. If you have ongoing joint inflammation despite standard treatments, this trial may offer a chance to try an investigational therapy under close monitoring.
This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This Phase 1/2 study tests whether fexofenadine (an allergy medicine) can improve symptoms and inflammation in people with active rheumatoid arthritis. Participants may be assigned to different treatment groups, and the study looks at safety and early signs of benefit.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
Hear when a new Arthritis, Rheumatoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.